Skip to main content

Table 2 Odds ratios for breast cancer according to duration of SSRI use during exposure time windows

From: A population-based case-control study of Selective Serotonin Reuptake Inhibitors (SSRIs) and breast cancer: The impact of duration of use, cumulative dose and latency

Exposure time window a No. of SSRI prescriptions Cases (n = 1,701) Controls (n = 17,017) Unadjusted OR b
(95% CI)
Adjusted OR c
(95% CI)
   n (%) n (%)   
≥2 years No use d (reference) 1,442 (84.8) 14,415 (84.7) 1.00 1.00
  1 to 35 215 (12.6) 2,178 (12.8) 0.99 (0.85, 1.15) 0.98 (0.84, 1.14)
  ≥36 44 (2.6) 424 (2.5) 1.04 (0.76, 1.42) 1.03 (0.75, 1.41)
2 to 7 years No use d (reference) 1,512 (88.9) 15,122 (88.9) 1.00 1.00
  1 to 35 157 (9.2) 1,614 (9.5) 0.97 (0.82, 1.16) 0.97 (0.82, 1.15)
  ≥36 32 (1.9) 281 (1.7) 1.14 (0.79, 1.65) 1.13 (0.78, 1.64)
>7 years No use d (reference) 1,556 (91.5) 15,528 (91.3) 1.00 1.00
  1 to 23 127 (7.5) 1,266 (7.4) 1.00 (0.83, 1.21) 1.00 (0.82, 1.21)
  ≥24 18 (1.0) 223 (1.3) 0.81 (0.50, 1.31) 0.80 (0.49, 1.29)
  1. OR = odds ratio; CI = confidence interval
  2. a Prior to index date.
  3. b Matched on age in five-year age groups but unadjusted for the influence of other risk factors.
  4. c Adjusted for age at index (years), marital status, income support status, residence status, and use of oral contraceptives and/or use of hormone therapy.
  5. d 'No use' (reference category) refers to women with no SSRI prescriptions dispensed during the specified time period evaluated.
  6. Note: Percentages may not add up to 100% due to rounding.